What Limits Spray-Dried Egg Powder Solubility in Oral Piglet Rehydration Systems?

Spray-dried whole egg and egg yolk powders intended as oral veterinary immunoglobulin sources are incorporated into piglet rehydration systems only after the spray-drying outlet temperature and the subsequent dry-blend moisture have been fixed within narrow bands. The powder is produced on co-current spray dryers at inlet temperatures of 140–170°C and outlet temperatures of 65–80°C, yielding a free-flowing solid with a moisture content of 3.0–5.0% and water activity below 0.35 when measured at 25°C. These limits are not arbitrary; water activity above 0.35 accelerates both microbial growth and lipid oxidation in the phospholipid-rich matrix, while outlet temperatures above 80°C reduce detectable anti-F4/F18 immunoglobulin titre. Batch release therefore includes titre determination by ELISA against the target fimbrial antigen, with acceptance limits tied to the specific piglet challenge model rather than to a single universal powder mass. The material is blended with glucose monohydrate, sodium citrate, and silicon dioxide in low-shear ribbon mixers before filling into 100 g sachets or 5 kg polyethylene-lined foil pouches.

In oral rehydration use, the powder is reconstituted in warm water at 35–40°C immediately before dosing through nipple or drench equipment. Field inclusion rates are not harmonised across manufacturers because the active immunoglobulin titre varies with spray-drying lot and egg source; published data for this specific configuration is limited to farm-level challenge trials rather than a single pharmacopoeial monograph. The dose is therefore calculated from measured anti-F4/F18 titre and piglet bodyweight, not from a fixed powder mass. Reconstitution with water above 45°C or with acidified electrolyte solutions below pH 4.5 causes measurable immunoglobulin denaturation and should be avoided. Batch-to-batch variance is controlled by blending at least three spray-drying sub-lots into a single bulk lot, followed by uniformity testing according to USP <905> for powdered dosage forms. The terminal product is a free-flowing oral granule or powder labelled for prophylactic use in neonatal piglets, with storage limited to ≤25°C and relative humidity below 60% to prevent caking and titre loss during farm storage.

In neonatal calf production, the decision to use egg yolk antibody powder in milk replacer is driven by farm-level rotavirus and coronavirus pressure and by the practical limits of reconstituting lipid-rich powders under cold water. The powder is typically incorporated into colostrum replacement or transition milk replacer at rates that are adjusted to the immunoglobulin titre against bovine rotavirus and coronavirus, with no universal inclusion level established under VICH GL18 stability guidance. Processing requires post-pasteurisation addition because the pasteurisation step in milk replacer plants operates at 72°C for 15 s, a time–temperature combination that inactivates the heat-labile antibody fraction. The recommended point of addition is after the plate heat exchanger and immediately before the high-shear mixer, where the powder is dispersed into cooled milk at 38–40°C. Batch equipment includes in-line rotor-stator mixers at 1500–3000 rpm, followed by surge tanks with low-speed agitators to avoid foam formation from the phospholipid and protein surface activity. The terminal package is a 200 g tub or 10 L bucket with an induction-sealed liner, and the label specifies use within 2 h of reconstitution under calf-barn conditions above 30°C because microbial growth in milk-based systems is rapid after rehydration.

Aqueous delivery through nipple drinker lines and header-tank proportioners exposes egg powder to shear, chlorine residuals, and residence times above 8 h at poultry-house temperatures. The powder is first dispersed into a stock solution at 20–50 g/L in a high-shear mixer with a pH-stat set to 6.5–7.0; citric acid monohydrate is used to buffer the solution because the natural pH drift of egg phospholipids under aeration can rise above 7.5, reducing suspension stability and promoting flocculation. The stock solution is then metered through a proportioner set to 1–2% into the main drinking-water line, giving a final dilution that varies with bird age and water consumption but is always below the concentration that produces visible foaming in nipple drinkers. The emulsion-like dispersion is unstable beyond 4 h at 30°C; field observations from proportioner-equipped poultry houses show separation into a lipid-rich upper layer and a sedimented protein lower layer when the stock tank is not continuously agitated. The stability boundary is therefore written into the farm protocol as a maximum stock holding time, not as an absolute concentration limit. The terminal product is a 1 L bottle or 20 L jug with a secondary closure for proportioner suction lines, labelled for oral administration only.

Drinking-Water Dispersibility, Lipid Oxidation, and pH Drift in Poultry Solutions

Compliance for this aqueous delivery route is governed by the hygiene requirements of Regulation (EC) No 183/2005/EC for feed business operators and by the veterinary medicinal product provisions of Regulation (EU) 2019/6 when the powder is marketed as an oral immunoglobulin active substance. Specific microbiological limits for the reconstituted solution follow the farm’s potable-water risk assessment, with total aerobic plate count not exceeding 10³ CFU/mL at the start of the holding period and residual free chlorine below 0.2 mg/L because chlorine at higher residuals has been shown to reduce measurable immunoglobulin titre in aqueous systems. The powder must also be free of Salmonella and Enterobacteriaceae when tested according to ISO 6579 and ISO 21528 methods. Since the formulation is not sterile and is not intended for parenteral use, the only heat treatment available is the pre-drying thermal burden already imparted during spray drying, and no terminal sterilisation step is applied. Every production lot therefore carries a certificate of analysis listing moisture content, water activity, immunoglobulin titre, and heavy-metal screen, with the limit for lead set below 2 mg/kg as a standard feed-grade contaminant threshold.

When Egg Powder Acts as a Low-Moisture Binder in Veterinary Chewable Tablets

Compression of veterinary chewable tablets containing egg powder is performed on rotary presses equipped with low-shear force feeders because the lipid fraction is pressure-sensitive and can build up on punch faces. The powder is first passed through a 0.5 mm screen and blended with dried liver powder, microcrystalline cellulose, crospovidone, and a powdered flavour system in a V-blender at 60–70% fill volume for 15–20 min. Tablet formulations typically use egg powder at 5–20% w/w, but the exact ratio is determined by the target tablet hardness and by the need to avoid excessive lubrication from the inherent phospholipid content. Compression runs at 8–15 kN main compression force on a 16-station rotary press produce tablets with breaking force of 60–120 N when tested under USP <1217>. Friability is measured according to USP <1216> and is maintained below 1.0% only when the blend moisture is below 4.0% and the press zone relative humidity is below 45%. At higher humidity, the powder absorbs moisture, punch adhesion increases, and tablet weight uniformity drifts outside the USP <905> acceptance limits for low-dose veterinary tablets.

For capsule filling, the same powder is granulated by slugging or low-shear wet granulation with a 10% w/v povidone solution, then dried to a final moisture content of 3.0–4.5% in a fluid-bed dryer with inlet air at 50–60°C. The dried granules are milled through a 1.0 mm screen and blended with 0.5–1.0% fumed silica to improve flow into the dosing disc of an automatic capsule filler. Capsule fill weight is controlled to ±3.0% using dose plungers with 5 mm compression pins, and the filled capsules are sealed with a locking mechanism to prevent oil migration from the egg powder into the shell. Terminal packaging is aluminium/PVC blister packs with a moisture vapour transmission rate below 0.5 g/m²/24 h, stored at ≤25°C. The batch failure mode most frequently observed on production lines is not mechanical but sensory: oxidation of the lipid fraction during storage produces rancid off-notes that are detectable in accelerated stability chambers at 40°C/75% RH within 4–8 weeks. This places the stability-limiting variable on the lipid oxidation index rather than on immunoglobulin titre for oral tablet and capsule formats.

Feed-mill premix lines handle egg powder as a mid-density carrier only after the powder has been passed through a 20-mesh sifter and conditioned to the ambient relative humidity of the mixer room. The material is blended with vitamin D₃, niacinamide, cobalt carbonate, and calcium carbonate in horizontal ribbon mixers with working capacities from 500 to 2000 kg; mixing time is set between 6 and 12 min at 40–60 rpm because longer mixing raises the blend temperature above 35°C and induces lipid smearing on the ribbon surfaces. The egg powder’s bulk density, usually 0.45–0.65 g/cm³, is sufficiently close to that of the mineral fraction to reduce segregation during silo discharge, but segregation is not eliminated. Field audits of premix silo discharge lines show batch-to-batch variance in egg powder concentration of ±8% when pneumatic conveying follows the mixer, so vacuum-type conveying is preferred over high-velocity airveyors. The terminal product is a 25 kg valve bag or 1000 kg big bag labelled as a vitamin-mineral premix for oral incorporation into complete feed, with storage humidity below 65% to prevent caking caused by the hygroscopic protein fraction.

The principal chemical incompatibility in premix applications is the trace-element package. Cupric sulphate pentahydrate and ferrous sulphate heptahydrate, commonly present at 0.5–2.0% in mineral premixes, catalyse free-radical oxidation of the phospholipid fraction and reduce immunoglobulin titre during storage. To manage this, the egg powder is either segregated from the mineral fraction by a two-stage mixing sequence or coated with a food-grade vegetable oil film prior to blending. The coating step is performed in a paddle coater at 800–1000 rpm for 3 min using 0.3–0.6% oil by mass, enough to reduce dust but not enough to clog the sifter. Stability testing under 25°C/60% RH conditions follows VICH GL18, with titre and peroxide value measured at 0, 3, 6, 9, and 12 months. The premix is used as a component of complete feed, but the final feed pelleting temperature must remain below 75°C; conditioning at 80–85°C for more than 30 s produces rapid immunoglobulin inactivation and is a known cause of field failure in pelleted creep feeds.

Parenteral Use of Whole-Egg Powders in Veterinary Formulation Is Constrained by Pharmacopoeial Pyrogen Limits

Whole egg powder retains immunogenic proteins and is neither depyrogenated nor sterilised by ordinary spray drying; consequently, pharmacopoeial monographs for parenteral preparations exclude this material from injectable veterinary products. The pyrogenic burden of egg-derived protein, combined with the presence of insoluble lipoproteins and the inability to pass a USP <151> rabbit pyrogen test or a USP <85> bacterial endotoxin test within injectable limits, places parenteral use outside the supported application space for this veterinary ingredient. No terminal sterilisation method is compatible with the native immunoglobulin structure, and filter sterilisation of an aqueous egg powder solution fails because the lipid fraction blocks 0.22 µm filters within seconds. Published data for this specific configuration is limited to negative safety determinations rather than efficacy studies, and no commercial injectable veterinary formulation based on whole egg powder is recognised under current regulatory frameworks.